Symptoms Of Covid-19

Part of a series on the
COVID-19 pandemic
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023 2024
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Animals Alzheimer's disease patients Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health symptoms Migration Military Notable deaths Other health issues Politics diplomacy Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Society Ireland Malaysia New Zealand Russia UK US
v t e

Symptoms of COVID-19 are variable, ranging from mild symptoms to severe illness.^[1][2] Common symptoms include headache,^[3] loss of smell^[4] and taste,^[5] nasal congestion and runny nose, cough, muscle pain, sore throat, fever,^[6] diarrhea, and breathing difficulties.^[7] People with the same infection may have different symptoms, and their symptoms may change over time. Three common clusters of symptoms have been identified: one respiratory symptom cluster with cough, sputum, shortness of breath, and fever; a musculoskeletal symptom cluster with muscle and joint pain, headache, and fatigue; a cluster of digestive symptoms with abdominal pain, vomiting, and diarrhea.^[7] In people without prior ear, nose, and throat disorders, loss of taste combined with loss of smell is associated with COVID-19.^[8]

Most people (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging) and 5% of patients suffer critical symptoms (respiratory failure, shock, or multiorgan dysfunction).^[9] At least a third of the people who are infected with the virus do not develop noticeable symptoms at any point in time.^{[10][11][12][13]} These asymptomatic carriers tend not to get tested and can spread the disease.^{[13][14][15][16]} Other infected people will develop symptoms later, called "pre-symptomatic", or have very mild symptoms and can also spread the virus.^[16]

As is common with infections, there is a delay between the moment a person first becomes infected and the appearance of the first symptoms. The median delay for COVID-19 is four to five days.^[17] Most symptomatic people experience symptoms within two to seven days after exposure, and almost all will experience at least one symptom within 12 days.^[17][18]

Most people recover from the acute phase of the disease. However, some people continue to experience a range of effects for months after recovery—named long COVID—and damage to organs has been observed. Multi-year studies are underway to further investigate the long-term effects of the disease.^[19]

Overview[edit | edit source]

Some symptoms of COVID-19 can be relatively non-specific; the most common symptoms are fever, dry cough, and fatigue.^[1][20] Among those who develop symptoms, approximately one in five may become more seriously ill and have difficulty in breathing. Emergency symptoms include difficulty in breathing, persistent chest pain or pressure, sudden confusion, difficulty waking, and bluish face or lips; immediate medical attention is advised if these symptoms are present.^[1] Further development of the disease can lead to complications including pneumonia, acute respiratory distress syndrome, sepsis, septic shock, and kidney failure.

Some symptoms usually appear sooner than others. In August 2020, scientists at the University of Southern California reported the "likely" order of initial symptoms of the COVID-19 disease as a fever followed by a cough and muscle pain, and that nausea and vomiting usually appear before diarrhea.^[21] This contrasts with the most common path for influenza where it is common to develop a cough first and fever later.^[21] While health agency guidelines tend to recommend isolating for 14 days while watching for symptoms to develop,^[22] there is limited evidence that symptoms may develop for some patients more than 14 days after initial exposure.^[23]

Systemic[edit | edit source]

Typical systemic symptoms include fatigue, and muscle and joint pains. Some people have a sore throat.^[1][2][20]

Fever[edit | edit source]

Fever is one of the most common symptoms in COVID-19 patients. However, its absence at an initial screening does not rule out COVID-19. Fever in the first week of a COVID-19 infection is part of the body's natural immune response; however, if the infections develop into a cytokine storm the fever is counterproductive. As of September 2020, little research had focused on relating fever intensity to outcomes.^[24]

A June 2020 systematic review reported a 75–81% prevalence of fever.^[2] As of July 2020, the European Centre for Disease Prevention and Control (ECDC) reported a prevalence rate of ~45% for fever.^[7]

Pain[edit | edit source]

A June 2020 systematic review reported a 27–35% prevalence of fatigue, 14–19% for muscle pain, 10–14% for sore throat.^[2] As of July 2020, the ECDC reported a prevalence rate of ~63% for muscle weakness (asthenia), ~63% for muscle pain (myalgia), and ~53% for sore throat.^[7]

Respiratory[edit | edit source]

Cough is another typical symptom of COVID-19, which could be either dry or a productive cough.^[2]

Some symptoms, such as difficulty breathing, are more common in patients who need hospital care.^[1] Shortness of breath tends to develop later in the illness.

Respiratory complications may include pneumonia and acute respiratory distress syndrome (ARDS).^{[25][26][27][28]}

As of July 2020, the ECDC reported a prevalence rate of ~68% for nasal obstruction, ~63% for cough, ~60% for rhinorrhoea.^[7] A June 2020 systematic review reported a 54–61% prevalence of dry cough and 22–28% for productive cough.^[2]

Cardiovascular[edit | edit source]

Cardiovascular complications may include heart failure, arrhythmias, heart inflammation, and blood clots.^{[29][30][31][32][33]}

Neurological[edit | edit source]

Patients with COVID-19 can present with neurological symptoms that can be broadly divided into central nervous system involvement, such as headache, dizziness, altered mental state, and disorientation, and peripheral nervous system involvement, such as anosmia and dysgeusia.^[34] Some patients experience cognitive dysfunction called "COVID fog", or "COVID brain fog", involving memory loss, inattention, poor concentration or disorientation.^[35][36] Other neurologic manifestations include seizures, strokes, encephalitis, and Guillain–Barré syndrome (which includes loss of motor functions).^[37][38]

As of July 2020, the ECDC reported a prevalence rate of ~70% for headache.^[7] A June 2020 systematic review reported a 10–16% prevalence of headache.^[2]

Loss of smell[edit | edit source]

In some people, COVID-19 causes people to temporarily lose their sense of smell.^[39][40]

This symptom, if it is present at all, often appears early in the illness.^[39] Its onset is often reported to be sudden. Smell usually returns to normal within a month. However, for some patients it improves very slowly and is associated with odors being perceived as unpleasant or different than they originally did (parosmia), and for some people smell does not return for at least many months.^[40] It is an unusual symptom for other respiratory diseases, so it is used for symptom-based screening.^[39][40]

Loss of smell has several consequences. Loss of smell increases foodborne illness due to inability to detect spoiled food, and may increase fire hazards due to inability to detect smoke. It has also been linked to depression. If smell does not return, smell training is a potential option.^[40]

It is sometimes the only symptom to be reported, implying that it has a neurological basis separate from nasal congestion. As of January 2021, it is believed that these symptoms are caused by infection of sustentacular cells that support and provide nutrients to sensory neurons in the nose, rather than infection of the neurons themselves. Sustentacular cells have many ACE2 receptors on their surfaces, while olfactory sensory neurons do not. Loss of smell may also be the result of inflammation in the olfactory bulb.^[40]

A June 2020 systematic review found a 29–54% prevalence of olfactory dysfunction for people with COVID-19,^[39] while an August 2020 study using a smell-identification test reported that 96% of people with COVID-19 had some olfactory dysfunction, and 18% had total smell loss.^[40] Another June 2020 systematic review reported a 4–55% prevalence of hyposmia.^[2] As of July 2020, the ECDC reported a prevalence rate of ~70% for loss of smell.^[7]

A disturbance in smell or taste is more commonly found in younger people, and perhaps because of this, it is correlated with a lower risk of medical complications.^[39]

Loss of taste[edit | edit source]

In some people, COVID-19 causes people to temporarily experience changes in how food tastes (dysgeusia or ageusia).^[39][40] Changes to chemesthesis, which includes chemically triggered sensations such as spiciness, are also reported. As of January 2021, the mechanism for taste and chemesthesis symptoms were not well understood.^[40]

A June 2020 systematic review found a 24–54% prevalence of gustatory dysfunction for people with COVID-19.^[39] Another June 2020 systematic review reported a 1–8% prevalence of hypogeusia.^[2] As of July 2020, the ECDC reported a prevalence rate of ~54% for gustatory dysfunction.^[7]

Other[edit | edit source]

Other neurological symptoms appear to be rare, but may affect half of patients who are hospitalized with severe COVID-19. Some reported symptoms include delirium, stroke, brain hemorrhage, memory loss, psychosis, peripheral nerve damage, anxiety, and post-traumatic stress disorder. Neurological symptoms in many cases are correlated with damage to the brain's blood supply or encephalitis, which can progress in some cases to acute disseminated encephalomyelitis. Strokes have been reported in younger people without conventional risk factors.^[41]

As of September 2020, it was unclear whether these symptoms were due to direct infection of brain cells, or of overstimulation of the immune system.^[41]

A June 2020 systematic review reported a 6–16% prevalence of vertigo or dizziness, 7–15% for confusion, and 0–2% for ataxia.^[2]

Other[edit | edit source]

Itchy rash in COVID. 61-year-old woman. Small erythematous spots are observed.

Chilblain-like lesions in a person with coronavirus infection.

Other symptoms are less common among people with COVID-19. Some people experience gastrointestinal symptoms such as loss of appetite, diarrhea, nausea or vomiting.^[1][42] A June 2020 systematic review reported a 8–12% prevalence of diarrhea, and 3–10% for nausea.^[2]

Less common symptoms include chills, coughing out blood, diarrhea, and rash.^[20] The so-called "COVID toes" are pink to violaceous papules arising on the hands and feet. These chilblain-like lesions often occur only in younger people and do not appear until late in the disease or during convalescence.^[43] Certain genetic polymorphisms (in the TREX1 gene) have been linked to susceptibility towards developing COVID-toe.^[44] A June 2020 systematic review reported a 0–1% prevalence of rash in COVID-19.^[2]

Approximately 20–30% of people who present with COVID-19 have elevated liver enzymes, reflecting liver injury.^[45][46]

Complications include multi-organ failure, septic shock, and death.^{[25][26][27][28]}

Longer-term effects[edit | edit source]

Multisystem inflammatory syndrome in children[edit | edit source]

Following the infection, children may develop multisystem inflammatory syndrome in children, also called paediatric multisystem inflammatory syndrome. This has symptoms similar to Kawasaki disease, which can be fatal.^[47][48][49]

Long COVID[edit | edit source]

References[edit | edit source]